Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TOWA Pharmaceutical Co's Enterprise Value is 円373,910 Mil.
TOWA Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円6,301 Mil. Therefore, TOWA Pharmaceutical Co's EV-to-FCF for today is 59.34.
The historical rank and industry rank for TOWA Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4553'
s EV-to-FCF Range Over the Past 10 Years
Min: -100.73 Med: -19.65 Max: 94.81
Current: 60.94
During the past 13 years, the highest EV-to-FCF of TOWA Pharmaceutical Co was 94.81. The lowest was -100.73. And the median was -19.65.
TSE:4553's EV-to-FCF is ranked worse than 78.67% of 572
companies
in the Drug Manufacturers industry
Industry Median: 21.06
vs TSE:4553: 60.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TOWA Pharmaceutical Co (TSE:4553) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TOWA Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
TOWA Pharmaceutical Co's share price for today is 円3870.00.
TOWA Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円106.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TOWA Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TOWA Pharmaceutical Co's EV-to-FCF falls into.
TOWA Pharmaceutical Co's current Enterprise Value is 円373,910 Mil.
TOWA Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,301 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOWA Pharmaceutical Co (TSE:4553) has a EV-to-FCF of 59.34 as of Aug. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TOWA Pharmaceutical Co and its competitors. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #450 out of 572 companies in the Drug Manufacturers industry, placing it in the top 78.7%.
Is TOWA Pharmaceutical Co's EV-to-FCF too high?
TOWA Pharmaceutical Co's current EV-to-FCF is 59.34. The Drug Manufacturers industry median EV-to-FCF is 21.06. TOWA Pharmaceutical Co's value of 59.34 is 181.8% above this industry median. Based on the distribution chart, TOWA Pharmaceutical Co ranks #450 out of 572 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TOWA Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #450 out of 572 companies for EV-to-FCF. This places TOWA Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 21.06. TOWA Pharmaceutical Co's value of 59.34 is 181.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 572 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TOWA Pharmaceutical Co's current EV-to-FCF of 59.34 is 181.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TOWA Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current EV-to-FCF is 59.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (TSE:4553) is currently considered Modestly Overvalued. The stock's GF Value™ is 円3,397.55, compared to a current price of 円3,870.00 — trading 13.9% above its estimated fair value. The current EV-to-FCF is 59.34 and 181.8% above the Drug Manufacturers industry median of 21.06. TOWA Pharmaceutical Co's overall GF Score™ is 87/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TOWA Pharmaceutical Co (TSE:4553), the current EV-to-FCF is 59.34 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TOWA Pharmaceutical Co (TSE:4553) Overvalued in 2026?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,870.00 is trading 13.9% above its estimated GF Value™ of 円3,397.55.
GuruFocus considers TOWA Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TSE:4553:
EV-to-FCF: 59.34
GF Value™: 円3,397.55 vs. price of 円3,870.00 (13.9% above fair value)
Industry Position: 181.8% above the Drug Manufacturers median (#450 of 572)
No single metric tells the full story. See the TSE:4553 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
87GF Score
Get the complete analysis for TSE:4553
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4553 has been successfully added to your 
